Browse News
Filter News
Found 77 articles
-
PFIZER REPORTS THIRD-QUARTER 2021 RESULTS
11/2/2021
Pfizer Inc. reported financial results for third-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3)
-
The osteoarthritis drug tanezumab gets permanent leave from the market. The decision of stopping production was due to negative feedback from the regulators.
-
Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential
10/26/2021
Eli Lilly and Company announced financial results for the third quarter of 2021.
-
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
8/3/2021
"We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies.
-
Pfizer Reports Second-quarter 2021 Results
7/28/2021
Pfizer Inc. reported financial results for second-quarter 2021 and raised 2021 guidance for revenues and Adjusted diluted EPS driven by its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE COVID-19 vaccine, as well as its business excluding BNT162b2.
-
argenx Appoints Karl Gubitz as Chief Financial Officer
6/1/2021
argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, announced the appointment of Mr. Karl Gubitz as Chief Financial Officer.
-
PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
5/4/2021
First-Quarter 2021 Revenues of $14.6 Billion, Reflecting 42% Operational Growth; Excluding Revenues for BNT162b2 of $3.5 Billion, Revenues Grew 8% Operationally Including a Negative 5% Impact from Pricing
-
Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance
4/27/2021
2021 EPS guidance lowered to be in the range of $7.03 to $7.23 on a reported basis and adjusted to be in the range of $7.80 to $8.00 on a non-GAAP basis.
-
Three days after U.S. Food and Drug Administration staff raised safety concerns over Pfizer’s and Eli Lilly’s NGF osteoarthritis drug tanezumab, an advisory panel has also posted its own objections.
-
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
3/25/2021
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab.
-
A briefing document from the U.S. FDA cites critical safety concerns with Pfizer and Eli Lilly’s anti-NGF osteoarthritis drug tanezumab, despite the fact that clinical trials have demonstrated the agent can help patients with osteoarthritis.
-
Pfizer Reports Third-Quarter 2020 Results
10/27/2020
Pfizer Inc. reported financial results for third-quarter 2020 and updated and tightened certain components of Total Company 2020 financial guidance, which continues to reflect actual and anticipated business impacts from the novel coronavirus disease of 2019 pandemic.
-
Lilly Reports Third-Quarter Financial Results, Updates Guidance
10/27/2020
Revenue in the third quarter of 2020 increased 5 percent driven by volume growth of 9 percent, while on a year-to-date basis revenue increased 6 percent driven by volume growth of 12 percent.
-
Many drug makers are investing in new science and hope to transition pain therapy approaches away from synthetic opioids. Biospace has tracked a few key alternative therapeutic candidates.
-
Results from multiple Phase III trials show consistent improvements in pain relief and physical function.
-
Pfizer Reports Second-Quarter 2020 Results
7/28/2020
Pfizer Inc. reported financial results for second-quarter 2020, increased its 2020 financial guidance for revenues and Adjusted diluted EPS and reaffirmed all other components of its 2020 financial guidance, which continues to reflect actual and anticipated business impacts from the novel coronavirus disease of 2019 pandemic.
-
Pfizer Reports First-Quarter 2020 Results
4/28/2020
First-Quarter 2020 Revenues of $12.0 Billion, Reflecting 7% Operational Decline; Excluding the Impact from Consumer Healthcare(1), Revenues Declined 1% Operationally
-
U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis
3/2/2020
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics
-
Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
7/30/2019
Eli Lilly and Company announced financial results for the second quarter of 2019.
-
PFIZER REPORTS SECOND-QUARTER 2019 RESULTS
7/29/2019
Pfizer Inc. reported financial results for second-quarter 2019 and updated certain components of its 2019 financial guidance.